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Cancer radiotherapy (RT) is involved in the treatment of more than a half of all cancer patients,
because it is highly effective; 40% of cancer cures can be attributed to RT (Baskar et al., 2012).
Moreover, the efficacy of RT is steadily improving, largely due to the striking progress in technology,
aimed at maximizing the radiation dose to the tumor and minimizing the dose to normal
tissues. This continual improvement contributes to the increasing numbers of cancer survivors.
In Australia, the 5-years relative survival from all cancers (excluding skin cancer) increased from
48% in 1984–1988 to 68% in 2009–20131. In 2012, 410,530 ex-cancer patients were alive 5 years
after treatment; 1.8% of the population. In the USA, there are now 14M cancer survivors; ∼4% of
the population (Travis, 2006; Travis et al., 2013). Accordingly, increasing attention is now directed
to the quality of life (QoL) of cancer survivors, particularly to treatment-related toxicities (Stone
et al., 2003; De Ruysscher et al., 2019), as highlighted in a recent report from the National Cancer
Research Institute in the UK2.
Normal tissue toxicity from RT can be attributed to three different etiologies. The most obvious
of these can be defined as “targeted”, due to relatively high radiation doses to normal tissues in
the vicinity of a tumor. Ironically, the technological improvements in dose delivery that have
diminished this problem, have contributed to the second category of normal tissue toxicity. Modern
RT techniques (e.g., Intensity-Modulated RT, IMRT) use multiple moving beams that sculpt a
volume of high dose encompassing the tumor, so quite large volumes of normal tissues are ‘bathed’
in low doses, within and between beams (Kry et al., 2005; Harrison, 2017). This category also
includes scattered radiation that spreads out in different directions from each radiation beam.
The third category can be considered as “systemic,” reflecting the radiation-induced abscopal
(“out-of-field”) effect (RIAE). This is attributed to the localized stress in the irradiated volume, that
triggers a systemic biological response that is propagated to sites distant from the irradiated volume,
and is largely mediated by the immune system (Reynders et al., 2015; Siva et al., 2015). In a sense,
the RIAE can be considered as the systemic counterpart of the cellular radiation-induced bystander
effect (RIBE), although the historical understanding of the phenomena was quite different. The
recognition of the RIBE (Nagasawa and Little, 1992; Prise and O’Sullivan, 2009) is much more
recent, compared to early observations the RIAE by radiation oncologists, that manifest both as
out-of-field tumor responses and out-of-field RT-associated toxicities (Mole, 1953; Siva et al., 2015).
The best-known RT-induced normal tissue toxicities are targeted effects (tissue responses in
the higher dose volume), the subject of many classical and contemporary radiobiological studies
(Stewart and Dorr, 2009). They can be acute (appear within weeks of irradiation), late (months to
years after RT), or both. For targeted effects, there is a wide spectrum of individual radiosensitivity
(RS) manifested as normal tissue toxicity (Barnett et al., 2009). Low dose- and RIAE-generated
“silent” toxicities, e.g., chronic inflammatory responses and mutagenesis in radiosensitive tissues,
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can also lead to long-term tissue dysfunction, even for future
generations (Dubrova, 2003). Just as it is well-established for
targeted effects, one can expect that there will be a spectrum of
individual RS for low dose and systemic effects.
Epidemiological findings in long-term cancer survivors
treated with RT indicate the increased incidence of degenerative
pathological conditions normally associated with aging,
or age-related diseases (e.g., cardio- and cerebrovascular
disorders, neurodegeneration including dementia, hormonal
disturbances, cataracts, bone marrow insufficiency, immune
system dysfunction, second cancers, and overall life shortening)
(Cupit-Link et al., 2017). Evidence is accumulating for similar
consequences of low dose IR exposure (Majer et al., 2014;
Harrison, 2017). Therefore, aging may be the common link
between the diverse late morbidities and RT. By amplifying the
mechanisms that are responsible for cellular aging (Sabatier
et al., 1995; Dubrova et al., 2002; Dubrova, 2003; Miller et al.,
2008; Paulino et al., 2010; Azzam et al., 2012; Sabatino et al.,
2012; Merrifield and Kovalchuk, 2013; Ungvari et al., 2013;
Sprung et al., 2015; Shimura et al., 2016; Yin et al., 2018), RT may
induce a premature aging manifested as an accelerated onset
of chronic degenerative disorders in some patients. Figure 1
highlights the similarities between the response to IR and aging,
but there are some differences, e.g., differences in the spectra
and severity of DNA lesions (Nikitaki et al., 2015). Premature
cellular senescence (Nakamura et al., 2008) is also an important
common feature of the two pathologies. It is important to note
that the idea of RT-induced accelerated aging is not a new one
(Richardson, 2009), but given the growing aging population,
it has increasingly important consequences for the cost of
community health care. Moreover, the availability of improved
biomarkers provides a means of monitoring both the need for
intervention, and the efficacy of proposed interventions.
Therefore, to fully understand the role of RT in accelerating
the aging process, research aimed at the following objectives
is required: (1) Development of a “signature” profile of
systemic markers to identify RT cancer patients susceptible to
development of premature aging; (2) Improving mechanistic
understanding of systemic propagation of genotoxic events and
the associated aging phenotype following local exposure to IR;
(3) Development of strategies for prevention, protection and
mitigation of RT-related systemic genotoxic events.
IDENTIFICATION OF A SIGNATURE OF
SYSTEMIC MARKERS FOR PREMATURE
AGING IN RT CANCER PATIENTS
The kinetics of aging biomarkers could be monitored in blood of
RT-treated cancer patients and compared with the pre-treatment
values. Suitable patients, scheduled for treatment with RT, would
be <50–60 years of age, and without evidence of non-cancer
morbidities at the time of work-up. Examples of a suitable
cohort would be breast or head & neck cancer patients, with an
anticipated 5-years survival >90%.
Studies indicate that accumulated unrepaired systemic DNA
damage underlies RT-induced pathologies (De Ruysscher et al.,
FIGURE 1 | RT amplifies processes reminiscent the biological hallmarks of
aging.
2019). The DNA damage response (DDR) varies in young,
mature and old mice, slow down with age, making old mice
the most vulnerable to radiation effects (Kovalchuk et al.,
2014). DDR declines in senescent cells and during normal and
premature human aging (Sedelnikova et al., 2008), and individual
RS continuously rises with age (Schuster et al., 2018). Novel
functional assays of radiation-induced DNA damage recognition
and repair efficiency in ex-vivo irradiated primary human
fibroblasts and peripheral blood mononuclear cells (PBMC) have
been recently developed. The tests are based on post-irradiation
formation of nuclear repair foci at the sites of DNA double-strand
breaks (DSBs) for two DNA damage markers, phosphorylated
ATM kinase (“ATM nucleo-shuttling”) (Bodgi and Foray, 2016;
Pereira et al., 2018) and histone H2AX (γ-H2AX) (Martin et al.,
2013; Lobachevsky et al., 2015a, 2016). Both assays efficiently
separated radiosensitive individuals with impaired DDR from
those with normal RS. In our retrospective study, ex-RT patients
who had documented to have severe RT-induced toxicity (and
matched controls who responded normally) were recalled for
blood sampling. A novel statistical algorithm was developed
by Lobachevsky et al. (2016), based on non-linear regression
analysis of the kinetics of repair of γ-H2AX foci, following ex-
vivo irradiation of the PBMC. Subsequently the same dataset
was analyzed by Bayesian modeling (Herschtal et al., 2018). Both
methods of analysis distinguished the radiosensitive patients
from controls, but the Bayesian statistics also outlined the
importance of assessment of both the initial radiation-induced
DNA damage and DNA damage repair. In a later study, the ex-
vivo γ-H2AX response was assayed in PBMC collected before and
during RT, and this showed that RT itself can affect individual
RS, as reflected by changes in DSB repair efficiency in PBMC
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(Yin et al., 2018), adding a further dimension to the challenge
of implementation.
Also, the number of endogenous γ-H2AX foci per cell in
PBMC of normal individuals increases with age in a linear
fashion (Sedelnikova et al., 2008; Schurman et al., 2012). The
outliers identified in the linear regression analysis (Schurman
et al., 2012) included elevated γ-H2AX foci/cell in patients with
clinical morbidities. Interestingly, DDR has been linked with the
immune response for normal and tumor tissues, as evidenced by
cumulative bioinformatics studies (Georgakilas et al., 2015).
Therefore, the numbers of γ-H2AX foci/cell and efficiency
of DDR in PBMC could provide a basis for identification
of RT patients susceptible to RT-induced premature aging.
However, it is more likely that a combination of markers will
be required to constitute an effective “signature” to identify
patients requiring added attention. Candidates for such auxiliary
biomarkers include those reflecting immune and epigenetic
alterations, increased immune cell senescence, oxidative stress,
and mitochondrial dysfunction.
IMPROVING THE MECHANISTIC
UNDERSTANDING OF SYSTEMIC
PROPAGATION OF GENOTOXIC EVENTS
AND THE ASSOCIATED AGING
PHENOTYPE FOLLOWING LOCAL
EXPOSURE TO IR
Conventional RT triggers systemic biological effects in animal
models (Koturbash et al., 2006, 2008; Mancuso et al., 2008), but
due to significant scatter, RIAEs are difficult to interpret. The
scatter problem associated with conventional radiation sources
is much reduced with Synchrotron radiation, providing a useful
tool to study RIAE. The defined geometry and coherence of
the synchrotron beam delivers IR to small volumes with lower
scatter, and the high dose rate (up to >1,000 Gy/sec) minimizes
motion artifacts, but also introduces the “FLASH” effect (Durante
et al., 2018). Ventura et al. (2017) reported that that various
synchrotron settings (IR dose, volume, beam modality) trigger
similar systemic effects in normal mouse tissues of wild-type
C57BL/6 mice. Depending on the level of scatter radiation
(Lobachevsky et al., 2015b), these effects were attributed to either
true abscopal signaling, or to direct low-dose scatter radiation.
RIAE was abrogated in mice with immune deficiencies, e.g.,
in mice with non-functional macrophages (Lobachevsky et al.,
2019). Possible extensions of these studies using synchrotron
irradiation include comparison of targeted and out-of-field
effects of IR in young and old mice of wild-type and immune-
deficient strains, as well as verification of salient features using a
model with conventional radiation beams. The objective would
be to understand the pathways by which IR modulates the
aging processes in various organs crucial for the development
of IR-related late pathologies (e.g., spleen, bone marrow, heart,
vasculature, gonads, brain). These experimental models could
also be used to evaluate potential therapeutic targets that emerge
from the clinical studies described in the previous section.
DEVELOPMENT OF STRATEGIES FOR
PREVENTION, PROTECTION AND
MITIGATION OF RT-RELATED SYSTEMIC
GENOTOXIC EVENTS
Targeted radiation effects and RIAE are both associated with
elevated DNA damage and genome instability mediated by
reactive oxygen species (ROS), so it is critical that any
strategy aimed at reducing systemic genotoxic events does not
compromise the cancer therapy, mediated by targeted radiation
effects. Similarly, whilst normal tissue toxicities associated RIAE
are mediated by the immune response, the tumor response
to RT also involves the immune response (Haikerwal et al.,
2015; Xing et al., 2019). However, kinetic studies on the impact
with immunomodulators on the response of targeted tumors,
out-of-field metastases and RIAE in normal tissues may reveal
differences in response kinetics enabling selective suppression of
RIAE in normal tissues. Such kinetic differences enabled scatter
effects to be distinguished from the systemic RIAE (Ventura et al.,
2017).
Our mouse studies revealed that molecules that block
cytokines/cytokine receptors and macrophages can be expected
to mitigate abscopal genotoxic events in normal tissues (Ventura
et al., 2017; Lobachevsky et al., 2019). Our extensive review of
potential strategies for prevention of RT-induced second cancers
(Martin et al., 2016) illustrates the range of approaches that
can be considered for all toxicities mediated by RIAE. A review
on radiation-induced cardiotoxicity (Stewart et al., 2013), which
noted the role of systemic effects, also discussed strategies for
prevention. Another report extensively reviewed strategies for
amelioration of radiation effects on the eye (Kleiman et al., 2017),
some of which could be applicable to RT. In this context, a
relatively new family of radioprotectors developed by one of the
authors (RFM) is of interest. The first example, methylproamine
(Martin et al., 2004), is a potent radioprotector in vitro; a
dose modification factor of 2.0 at a concentration of 10 uM
(Lobachevsky et al., 2011) and improved analogs, including
in vivo activity, have been reported in the patent literature
(Martin et al., 2011). Such radioprotectors have the potential
to take advantage of the slow kinetics observed for the RIAE,
illustrated by the report of the delayed appearance of DNA
damage in eyebrow hair follicles after RT of lung cancer patients;
24 h after the first fraction (Siva et al., 2015). A delayed DDR
is well-established for the cellular RIBE (Sedelnikova et al.,
2007). Interestingly, methylproamine protects bystander cells
in the in vitro RIBE setting, e.g., if present with recipient
cells at the time of transfer of media irradiated cells (Burdak-
Rothkamm et al., 2015). By contrast, in the context of targeted
radiation effects, methylproamine must be present before and
during irradiation to endow radioprotection of cultured cells
(Lobachevsky et al., 2011), consistent with themechanism (DNA-
binding antioxidant) of radioprotection (Martin and Anderson,
1998). Thus, one can envisage an RT scenario in which such
radioprotectors could be administered after irradiation, and thus
not compromise response of the tumor, but nevertheless mitigate
the subsequent RIAE mediated toxicity in normal tissues.
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Whilst scheduling that avoids the possibility of compromising
the tumor response might be challenging in the setting of
conventional fractionation, this would be less problematical for
hypofractionation modalities.
CONCLUSIONS
RT has an established role in cancer therapy and is unlikely
to be superseded in the foreseeable future. In addition to
pursuing better treatments, it is time now for more focus
on the QoL of cancer RT survivors. The priorities include
the need to understand the biological basis of treatment
side-effects and their management, and, in particular, the
mechanisms responsible for RT-induced aging phenotype and
associated pathologies. This new knowledge is expected
to enable development of systemic markers to identify
patients most susceptible to accelerated aging, and the
early stages of that process, as well as novel interventions
for prevention and mitigation. Thus, the overall objective is
early diagnosis, monitoring and management of RT-related
morbidities, and identification of those cancer patients at
most risk of these morbidities so their treatments can be
modified accordingly.
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